Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience

BACKGROUND: Despite the wide spread use of trastuzumab in human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric cancer patients, its optimal duration of administration beyond first-line disease progression is unknown. In HER2 overexpressing metastatic breast cancer, trast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Al-Shamsi, Humaid O., Fahmawi, Yazan, Dahbour, Ibrahim, Tabash, Aziz, Rogers, Jane E., Mares, Jeannette Elizabeth, Blum, Mariela A., Estrella, Jeannelyn, Matamoros, Aurelio, Sagebiel, Tara, Devine, Catherine E., Badgwell, Brian D., Lin, Quan D., Das, Prajnan, Ajani, Jaffer A.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963369/
https://ncbi.nlm.nih.gov/pubmed/27563438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados